OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial
Hartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
The Lancet Haematology (2023) Vol. 10, Iss. 7, pp. e495-e509
Closed Access | Times Cited: 40
Hartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
The Lancet Haematology (2023) Vol. 10, Iss. 7, pp. e495-e509
Closed Access | Times Cited: 40
Showing 26-50 of 40 citing articles:
Immunotherapeutic Potential of Mutated NPM1 for the Treatment of AML
Jochen Greiner, Eithar Mohamed, Daniel Fletcher, et al.
(2024)
Open Access | Times Cited: 1
Jochen Greiner, Eithar Mohamed, Daniel Fletcher, et al.
(2024)
Open Access | Times Cited: 1
High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia
Shuki Oya, Hidetoshi Ozawa, Satoshi Morishige, et al.
International Journal of Hematology (2024) Vol. 120, Iss. 3, pp. 297-304
Closed Access | Times Cited: 1
Shuki Oya, Hidetoshi Ozawa, Satoshi Morishige, et al.
International Journal of Hematology (2024) Vol. 120, Iss. 3, pp. 297-304
Closed Access | Times Cited: 1
Immune‐dysregulation harnessing in myeloid neoplasms
Mohammad Jafar Sharifi, Ling Xu, Nahid Nasiri, et al.
Cancer Medicine (2024) Vol. 13, Iss. 17
Open Access | Times Cited: 1
Mohammad Jafar Sharifi, Ling Xu, Nahid Nasiri, et al.
Cancer Medicine (2024) Vol. 13, Iss. 17
Open Access | Times Cited: 1
Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia
Jochen Greiner, Eithar Mohamed, Daniel Fletcher, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3443-3443
Open Access | Times Cited: 1
Jochen Greiner, Eithar Mohamed, Daniel Fletcher, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3443-3443
Open Access | Times Cited: 1
Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?
Jad Othman, Richard Dillon
The Lancet Haematology (2023) Vol. 10, Iss. 7, pp. e478-e479
Closed Access | Times Cited: 3
Jad Othman, Richard Dillon
The Lancet Haematology (2023) Vol. 10, Iss. 7, pp. e478-e479
Closed Access | Times Cited: 3
Genetic, Phenotypic, and Clinical Heterogeneity of NPM1-Mutant Acute Myeloid Leukemias
Ugo Testa, Elvira Pelosi, Germana Castelli
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1805-1805
Open Access | Times Cited: 2
Ugo Testa, Elvira Pelosi, Germana Castelli
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1805-1805
Open Access | Times Cited: 2
Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia
Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, et al.
Haematologica (2024)
Open Access
Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, et al.
Haematologica (2024)
Open Access
Membrane Antigen Targeting in Acute Myeloid Leukemia Using Antibodies or CAR-T Cells
Ugo Testa, Germana Castelli, Elvira Pelosi
Cancers (2024) Vol. 16, Iss. 21, pp. 3627-3627
Open Access
Ugo Testa, Germana Castelli, Elvira Pelosi
Cancers (2024) Vol. 16, Iss. 21, pp. 3627-3627
Open Access
Novel combinations of CD33-targeted immunotherapies
Tongyuan Xue, M L Chen, J Y Gong, et al.
Elsevier eBooks (2024), pp. 233-251
Closed Access
Tongyuan Xue, M L Chen, J Y Gong, et al.
Elsevier eBooks (2024), pp. 233-251
Closed Access
Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review
Brian D. Adkins, Daniel K. Noland, Tamra Slone, et al.
Journal of Clinical Apheresis (2024) Vol. 39, Iss. 3
Open Access
Brian D. Adkins, Daniel K. Noland, Tamra Slone, et al.
Journal of Clinical Apheresis (2024) Vol. 39, Iss. 3
Open Access
Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia
Joseph F. Mort, David Brighton, Samantha DiBenedetto, et al.
European Journal Of Haematology (2024)
Open Access
Joseph F. Mort, David Brighton, Samantha DiBenedetto, et al.
European Journal Of Haematology (2024)
Open Access
How to improve AML outcomes?
Taner Tan, Sinem Civriz Bozdağ
Blood Research (2024) Vol. 59, Iss. 1
Open Access
Taner Tan, Sinem Civriz Bozdağ
Blood Research (2024) Vol. 59, Iss. 1
Open Access
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient
Michael Heuser, Rabia Shahswar
Hematology (2024) Vol. 2024, Iss. 1, pp. 158-167
Closed Access
Michael Heuser, Rabia Shahswar
Hematology (2024) Vol. 2024, Iss. 1, pp. 158-167
Closed Access
All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results
Amar H. Kelkar, Shai Shimony, Edward R. Scheffer Cliff, et al.
The Lancet Haematology (2023) Vol. 10, Iss. 9, pp. e706-e707
Closed Access
Amar H. Kelkar, Shai Shimony, Edward R. Scheffer Cliff, et al.
The Lancet Haematology (2023) Vol. 10, Iss. 9, pp. e706-e707
Closed Access
All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results – Authors' reply
Hartmut Döhner, Axel Benner, Arnold Ganser
The Lancet Haematology (2023) Vol. 10, Iss. 9, pp. e707-e707
Closed Access
Hartmut Döhner, Axel Benner, Arnold Ganser
The Lancet Haematology (2023) Vol. 10, Iss. 9, pp. e707-e707
Closed Access
